Rate My Professor Ashley Frazer-Abel

Frazer-Abel has published extensively on these topics in high-impact journals. Key publications include "Association of Carboxypeptidase B2 Gene Polymorphisms With Graft Loss in Kidney Transplantation" (Transplant Direct, 2026), "A single-arm phase 2 trial of an investigational RNA therapeutic to complement factor B sefaxersen for treatment of IgA nephropathy" (Kidney Int, 2026), "Autoantibodies reactive with glomerular endothelial cells and podocytes in patients with membranous nephropathy" (J Transl Autoimmun, 2026), "Biomarkers in the Management of Complement-Mediated Kidney Diseases in the Era of Complement Therapeutics" (Clin J Am Soc Nephrol, 2025), "Genetic mapping of complement system proteins for islet autoimmunity in children with high risk of T1D" (Commun Biol, 2025), "A Phase 2 Trial of Hydroxychloroquine in Individuals at Risk for Rheumatoid Arthritis" (Arthritis Rheumatol, 2025), and "Dynamic Risk of Systemic Complement Activation With Time to Progression to Advanced Age-Related Macular Degeneration" (JAMA Ophthalmol, 2025). She was Principal Investigator on NIH grant F32AI050392 for "Mechanisms of Nicotine Induced Immunosuppression" (2002-2005). Frazer-Abel has contributed to external quality assurance programs for complement laboratories and served in editorial roles, including for Frontiers in Immunology on autoantibodies in kidney diseases. Her expertise advances diagnostics and therapeutics for complement-mediated conditions.